slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 87,481-87,510
Pages 3,685
Rows per page 30
Component
87,481-87,510 of 110,539
42
The slide uses a before-and-after diagram to illustrate the mechanism of action.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
43
The chart shows a scatter plot with a regression line indicating a correlation coefficient (rho) of 0.86.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
45
The slide uses a process flow diagram to illustrate the study design (Part A to Part B).23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
46
The slide outlines the mechanism of action, clinical rationale, and upcoming Phase 2a study design for the drug candidate.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
48
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
50
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
56
Uses a linguistic analogy to explain genetic imputation.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
57
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
01
Includes company logo and imagery representing various business segments.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Attention1 hit
04
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Attention1 hit
07
The central diagram is a hub-and-spoke model representing 'The Engine' supported by Technology, Infrastructure, Data Science, Integration, and Experts.AbCellera | Investor Conference Presentation Deck | 19 slides · AbCellera
Conference presentation Investor relations Beat · Solution & ApproachLoop · Golden Circle1 hit
10
Part of a series of slides defining business model segments.AbCellera | Investor Conference Presentation Deck | 19 slides · AbCellera
Conference presentation Investor relations Beat · Evidence & Proof1 hit
10
The slide highlights six specific parameters: Target, Affinity, Epitope, Developability, Manufacturability, and Immunogenicity.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
15
The diagram is a circular flywheel process showing the integration of data, wet lab validation, and AI creation.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
17
The slide illustrates a process flow from target antigen/epitope to AI-generated antibody scaffold, followed by wet lab validation (ACE/SPR assays) to identify binders.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
18
The slide uses a four-column layout to categorize value propositions, each supported by a visual icon or diagram.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
19
Uses a timeline comparison to illustrate value proposition.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
26
The slide uses a growth curve (exponential) to visualize progress over time.Absci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
27
Absci | Investor Presentation Deck | 27 slidesAbsci | Investor Presentation Deck | 27 slides · Absci
Pitch deck Investor relations Beat · Action1 hit
07
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the patient burden.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
19
The slide uses a heatmap to visualize individual patient outcomes, highlighting clinical improvement vs. worsening.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/kg dose.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
31
Box plot visualization of clinical trial results.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Attention1 hit
07
The slide includes a disclaimer regarding the date of the expectations and a note about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit